![1]()
News
Cilostazol plus aspirin or clopidogrel reduces the risk of recurrent stroke
February 7, 2019
HONOLULU – Dual therapy with cilostazol and aspirin or clopidogrel did not increase the risk of serious bleeding.
![1]()
News
Intensive insulin added no benefit for hyperglycemia after ischemic stroke
February 7, 2019
Results from a large RCT showed intensive and standard insulin regimens produced similar clinical outcomes after an acute ischemic stroke.
![1]()
News
Pulmonary hypertension linked to complications after head and neck procedures
February 1, 2019
SAN DIEGO – The odds of in-hospital mortality were not significantly different for those with PHTN.
![1]()
News
Aspirin for primary cardiovascular prevention, RIP
January 30, 2019
SNOWMASS, COLO. – “Is aspirin safe and effective for primary prevention? The short answer here is no.” –Dr. Patrick T. O’Gara
![1]()
News
Subclinical hypothyroidism boosts immediate risk of heart failure
January 24, 2019
CHICAGO – Large Danish study links subclinical and overt hypothyroidism to immediate risk of heart failure.
![1]()
News
Obesity paradox applies to post-stroke mortality
January 17, 2019
CHICAGO – Overweight and obese VA stroke patients have lower 30-day and 1-year all-cause mortality after an in-hospital stroke.
![1]()
News
SGLT-2 inhibitors promising for heart failure prevention, not treatment
January 12, 2019
LOS ANGELES – The combination of heart failure and diabetes is particularly lethal.
![1]()
News
RE-SPECT ESUS: Dabigatran matched aspirin for second stroke prevention
January 9, 2019
MONTREAL – In an international trial with 5,390 patients, dabigatran proved no better than aspirin for second stroke prevention following ESUS.
![1]()
News
New diabetes drugs solidify their cardiovascular and renal benefits
January 7, 2019
CHICAGO – Empagliflozin’s heart failure and renal benefits surprised when reported in 2015. The evidence has grown stronger and broader since.
![1]()
News
Can higher MAP post cardiac arrest improve neurologic outcomes?
December 21, 2018
CHICAGO – A target mean arterial pressure higher than what the guidelines recommend appears safe but has mixed results for improving neurologic outcomes.
